Human Pharmacology of Ayahuasca: Subjective and Cardiovascular Effects, Monoamine Metabolite Excretion, and Pharmacokinetics
- J. Riba, M. Valle, G. Urbano, M. Yritia, A. Morte, M. Barbanoj
- Medicine, BiologyJournal of Pharmacology and Experimental…
- 1 July 2003
Drug administration increased urinary normetanephrine excretion, but, contrary to the typical MAO-inhibitor effect profile, deaminated monoamine metabolite levels were not decreased, suggesting a predominantly peripheral (gastrointestinal and liver) site of action for harmine.
Subjective effects and tolerability of the South American psychoactive beverage Ayahuasca in healthy volunteers
Ayahuasca can be described as inducing changes in the perceptual, affective, cognitive, and somatic spheres, with a combination of stimulatory and visual psychoactive effects of longer duration and milder intensity than those previously reported for intravenously administered DMT.
Pattern of use and subjective effects of Salvia divinorum among recreational users.
Dopamine Agonist Increases Risk Taking but Blunts Reward-Related Brain Activity
The use of D2/D3 dopaminergic agonists in Parkinson's disease (PD) may lead to pathological gambling. In a placebo-controlled double-blind study in healthy volunteers, we observed riskier choices in…
Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a preliminary report.
OBJECTIVES Ayahuasca (AYA), a natural psychedelic brew prepared from Amazonian plants and rich in dimethyltryptamine (DMT) and harmine, causes effects of subjective well-being and may therefore have…
Personality, Psychopathology, Life Attitudes and Neuropsychological Performance among Ritual Users of Ayahuasca: A Longitudinal Study
Ayahuasca is an Amazonian psychoactive plant beverage containing the serotonergic 5-HT2A agonist N,N-dimethyltryptamine (DMT) and monoamine oxidase-inhibiting alkaloids (harmine, harmaline and…
Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial
New evidence is brought new evidence supporting the safety and therapeutic value of ayahuasca, dosed within an appropriate setting, to help treat depression, in the first controlled trial to test a psychedelic substance in treatment-resistant depression.
Ayahuasca: Pharmacology, neuroscience and therapeutic potential
Antidepressant Effects of a Single Dose of Ayahuasca in Patients With Recurrent Depression: A SPECT Study
- R. Sanches, F. de Lima Osório, J. Hallak
- PsychologyJournal of Clinical Psychopharmacology
- 1 February 2016
The results suggest that ayahuasca may have fast-acting and sustained antidepressive properties and should be replicated in randomized, double-blind, placebo-controlled trials.
Increased frontal and paralimbic activation following ayahuasca, the pan-amazonian inebriant
- J. Riba, S. Romero, E. Grasa, E. Mena, I. Carrió, M. Barbanoj
- Psychology, BiologyPsychopharmacology
- 31 March 2006
The present results suggest that ayahuasca interacts with neural systems that are central to interoception and emotional processing and point to a modulatory role of serotonergic neurotransmission in these processes.